Modality
ASO
MOA
EGFRi
Target
RET
Pathway
Fibrosis
HCCRA
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
Jul 2019
→ Sep 2028
Phase 1Current
NCT03659725
295 pts·HCC
2019-07→2028-09·Not yet recruiting
295 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-152.5y awayInterim· HCC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2028-09-15 · 2.5y away
HCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03659725 | Phase 1 | HCC | Not yet recr... | 295 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D |